Action BNTX BIONTECH SE
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués BioNTech SE

Actions

BNTX

US09075V1026

Temps réel estimé Cboe BZX
Autres places de cotation
 19:52:13 10/06/2024 		Varia. 5j. Varia. 1 janv.
97,6 USD -2,74 % Graphique intraday de BioNTech SE -4,99 % -7,39 %
17:15 Les actions européennes négociées aux États-Unis sous la forme de certificats de dépôt américains sont en baisse lundi matin MT
08:24 L'Indonésie intensifie la lutte contre la tuberculose en raison des inquiétudes concernant l'impact économique RE

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
BioNTech : ASCO 2024
PU
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
AQ
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
GL
Patents, Policies And Privacy: The Highs And Lows Of Technology In IP
AQ
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
AQ
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 17 May 2024)
PU
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 1 June 2022)
PU
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 22 June 2021)
PU
BioNTech : Publication of the resolutions and system for the remuneration of the members of the management Board (resolution of the AGM on 17 May 2024)
PU
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GL
MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership
PR
BioNTech : to Evaluate NanoTag’s Target Labeling System in Different Therapeutic Areas
PU
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
GL
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GL
BioNTech : Corporate Presentation
PU
BioNTech : First Quarter 2024 Financial Report
PU
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
GL
Moderna Litigation Against BioNTech And Pfizer Stayed Pending IPR
AQ
GSK Sues Pfizer, Pharmacia & Upjohn & BioNTech For Infringing MRNA Vaccine Patents
AQ
BioNTech : Joint report of the Management Board of BioNTech SE and the management of BioNTech Collaborations GmbH on the domination and profit and loss transfer agreement pursuant to Section 293a AktG
PU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BNTX
  4. Actualités BioNTech SE
  5. Communiqués